Now in the end stretch of fiscal 2018, the final year in its current three-year medium-term management plan, Sumitomo Chemical…...
Please subscribe to read the full story.
Nihon Medi-Physics
PeptiDream, Nihon Medi-Physics Plan Joint R&D for Simultaneous Diagnosis and Treatment of Cancer
PeptiDream Inc. (TYO:4587) and Nihon Medi-Physics Co. Ltd. (NMP) announced on Dec. 18 that they intend to conduct joint efforts…...
Please subscribe to read the full story.
Nihon Medi-Physics Embarks on Development of New Cancer Treatment
Nihon Medi-Physics Co. Ltd., a radiopharmaceutical manufacturing venture equally funded by Sumitomo Chemical Co. Ltd. (TYO:4005) and GE Healthcare, will…...
Please subscribe to read the full story.
